[go: up one dir, main page]

DE69635079D1 - Verwendung von il-11 zur behandlung von entzündung - Google Patents

Verwendung von il-11 zur behandlung von entzündung

Info

Publication number
DE69635079D1
DE69635079D1 DE69635079T DE69635079T DE69635079D1 DE 69635079 D1 DE69635079 D1 DE 69635079D1 DE 69635079 T DE69635079 T DE 69635079T DE 69635079 T DE69635079 T DE 69635079T DE 69635079 D1 DE69635079 D1 DE 69635079D1
Authority
DE
Germany
Prior art keywords
disorders
arthritis
inflammation
treatment
cva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69635079T
Other languages
English (en)
Other versions
DE69635079T2 (de
Inventor
James Keith
Paul Schendel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE69635079D1 publication Critical patent/DE69635079D1/de
Publication of DE69635079T2 publication Critical patent/DE69635079T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
DE69635079T 1995-06-27 1996-05-30 Verwendung von il-11 zur behandlung von entzündung Expired - Fee Related DE69635079T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US495724 1995-06-27
US08/495,724 US5679339A (en) 1995-06-27 1995-06-27 Method of using IL-11 for treating spondyloarthropies
PCT/US1996/008059 WO1997001353A1 (en) 1995-06-27 1996-05-30 Use of il-11 to treat inflammation

Publications (2)

Publication Number Publication Date
DE69635079D1 true DE69635079D1 (de) 2005-09-22
DE69635079T2 DE69635079T2 (de) 2006-06-29

Family

ID=23969764

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635079T Expired - Fee Related DE69635079T2 (de) 1995-06-27 1996-05-30 Verwendung von il-11 zur behandlung von entzündung

Country Status (8)

Country Link
US (4) US5679339A (de)
EP (2) EP0835128B1 (de)
JP (1) JPH11508556A (de)
AT (1) ATE302022T1 (de)
AU (1) AU724626B2 (de)
CA (1) CA2220554A1 (de)
DE (1) DE69635079T2 (de)
WO (1) WO1997001353A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887461B1 (en) * 1998-10-26 2005-05-03 Genetics Institute, Llc Method of using IL-11 for treating mucositis
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
AUPO439396A0 (en) * 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
US6660258B1 (en) * 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
US6953777B2 (en) * 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
CA2345920A1 (en) * 1999-04-15 2001-02-01 Genetics Institute, Inc. Use of interleukin-11 to treat gastrointestinal disorders
JP2003522735A (ja) * 1999-07-15 2003-07-29 ジェネティクス インスティチュート，エルエルシー Ｉｌ−１１に関する組成物
US6248718B1 (en) 1999-08-18 2001-06-19 Atlantic Biomed Corporation Lesion-directed dry dosage forms of antibacterial agents for the treatment of acute mucosal infections of the oral cavity
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
CN1688293A (zh) * 2002-09-16 2005-10-26 韦思公司 多肽治疗剂口服给药的缓释配方及其使用方法
US20040121991A1 (en) * 2002-12-20 2004-06-24 Araneo Barbara A. Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
JP5191393B2 (ja) * 2006-10-27 2013-05-08 国立大学法人大阪大学 インターロイキン１１の心疾患治療薬としての利用
US20100119476A1 (en) * 2007-03-05 2010-05-13 University Of North Carolina At Chapel Hill Selection of peptides specific for human blood outgrowth endothelial cells
US8426367B2 (en) * 2007-03-05 2013-04-23 The University Of North Carolina At Chapel Hill Peptides specific for human blood outgrowth endothelial cells
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011154413A1 (en) 2010-06-07 2011-12-15 Fritz-Lipmann-Insitut E. V. Leibniz-Institut Für Altersforschung Agent against glucocorticoid-induced osteoporosis
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017201322A1 (en) * 2016-05-19 2017-11-23 Cortexyme, Inc. Treatment of osteoarthritis with gingipain blocking agents
BR112019012342A2 (pt) 2016-12-16 2019-11-26 Nat Univ Singapore anticorpos il-11
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
WO2020152122A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia

Also Published As

Publication number Publication date
US6270759B1 (en) 2001-08-07
EP0835128B1 (de) 2005-08-17
DE69635079T2 (de) 2006-06-29
AU724626B2 (en) 2000-09-28
US5958401A (en) 1999-09-28
CA2220554A1 (en) 1997-01-16
WO1997001353A1 (en) 1997-01-16
US5679339A (en) 1997-10-21
AU6250596A (en) 1997-01-30
ATE302022T1 (de) 2005-09-15
EP1579868A3 (de) 2005-10-19
US5948402A (en) 1999-09-07
EP0835128A1 (de) 1998-04-15
EP1579868A2 (de) 2005-09-28
JPH11508556A (ja) 1999-07-27

Similar Documents

Publication Publication Date Title
DE69635079D1 (de) Verwendung von il-11 zur behandlung von entzündung
DE69908648D1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
DE69434773D1 (de) Vorrichtung zur schnellen thermischen Behandlung zur Herstellung von Halbleiterwafern
DE69841421D1 (de) Die verwendung von einem steroidsaponin zur behandlung von demenz
ATE149483T1 (de) Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
DE69020221D1 (de) Verfahren zur Bildung von amorphes Siliziumcarbid enthaltenden Beschichtungen.
DE69413138D1 (de) Verfahren zur Bildung von Beschichtungen aus kristallinem Siliziumcarbid
EP1049664A4 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE69431385D1 (de) Verfahren zur Herstellung von Silizium-Halbleiterplättchen
DE69224080D1 (de) Verwendung von nsaid zur behandlung von demenz
DE68916699D1 (de) Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
DE59404999D1 (de) Verfahren zur Herstellung anorganischer diffraktiver Elemente und Verwendung derselben
DE69500407D1 (de) Verfahren zur Herstellung von Siliciumcarbidmaterial
DE59400669D1 (de) Verfahren zur nasschemischen Behandlung von Werkstücken
DE69107992D1 (de) Verfahren zur elektrolytischen Herstellung von Ozon und Vorrichtung dazu.
DE69432796D1 (de) Kombination von dna-sequenzen, die die bildung von modifizierter stärke in pflanzenzellen und pflanzen ermöglicht, verfahren zur herstellung dieser pflanzen
DE59505870D1 (de) Verfahren zum Herstellen von keramischen Bauteilen aus Siliziumcarbid
DE3883518D1 (de) Verfahren zur Herstellung von Silicium-Metall hoher Reinheit und Vorrichtung dafür.
ATE171176T1 (de) 1-(substituierte pyridinylamino)-1h-indol-5-yl substituierte carbamate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FI883961A0 (fi) Farmaceutiskt nyttig polymorfisk modifikation av buspiron.
DE69715188D1 (de) Verfahren und zwischenprodukte zur herstellung von 4-trifluoromethylbiphenyl-2-carbonsaüre,(2-(2h-(1,2,4) triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
NO953051L (no) Fremgangsmåte og anordning for regulering av avvanning av suspensjoner
DE50209564D1 (de) Vorrichtung und Verfahren zum Messen der Konzentration von Ionen in einer Messflüssigkeit
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ATE153084T1 (de) Verfahren zur elektrochemischen synthese von organosiliciumverbindungen sowie eine vorrichtung zur durchführung des verfahrens und ihre verwendung zur herstellung von organosiliciumverbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee